Gene: ASXL1

171023
BOPS|MDS
ASXL transcriptional regulator 1
protein-coding
20q11.21
Ensembl:ENSG00000171456 MIM:612990 Vega:OTTHUMG00000032218 UniprotKB:Q8IXJ9
NG_027868.1
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
8.613e-1 (AD)  2.007e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ZZEF10.93
CHD80.927
SETD50.924
GTF3C20.922
SETDB10.92
TTC170.912
RBM250.912
EP4000.911
GTPBP20.91
RBM50.908

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.595
OR4F29-0.564
KLRC2-0.277
DIAPH3-0.257
OR4F16-0.236
TRDN-0.215
GSDMC-0.204
PLA2G5-0.202
MTRNR2L9-0.201
MTRNR2L6-0.198

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C49562614-deoxy-11,12-didehydroandrographolide"14-deoxy-11,12-didehydroandrographolide results in decreased expression of ASXL1 mRNA"22101062
C0230353,4,5,3',4'-pentachlorobiphenyl"3,4,5,3',4'-pentachlorobiphenyl results in increased expression of ASXL1 mRNA"28973690
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with methylmercuric chloride co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASXL1 mRNA"27188386
C517041(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)"(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II) results in decreased expression of ASXL1 mRNA"19561079
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with methylmercuric chloride co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASXL1 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of ASXL1 mRNA21420995
D000082AcetaminophenAcetaminophen results in increased expression of ASXL1 mRNA22230336
D000082AcetaminophenAcetaminophen affects the expression of ASXL1 mRNA17562736
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of ASXL1 gene27153756
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of ASXL1 mRNA19770486
C015001arsenitearsenite results in increased methylation of ASXL1 promoter23974009
D001554BenzeneBenzene results in increased expression of ASXL1 mRNA19162166
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of ASXL1 mRNA"19150397|2001819
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of ASXL1 mRNA"20382639
C044887beta-methylcholinebeta-methylcholine affects the expression of ASXL1 mRNA21179406
C006780bisphenol Abisphenol A affects the expression of ASXL1 mRNA25181051
D020122tert-Butylhydroperoxidetert-Butylhydroperoxide results in decreased expression of ASXL1 mRNA15336504
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ASXL1 gene20938992
C018021cobaltous chloridecobaltous chloride results in increased expression of ASXL1 mRNA24386269
D019327Copper SulfateCopper Sulfate results in decreased expression of ASXL1 mRNA19549813
D003703DemecolcineDemecolcine results in increased expression of ASXL1 mRNA23649840
C014476diethyl maleatediethyl maleate results in decreased expression of ASXL1 mRNA25270620
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ASXL1 gene20938992
D005557FormaldehydeFormaldehyde results in increased expression of ASXL1 mRNA23649840
D005947Glucose[INS protein co-treated with Glucose] results in increased expression of ASXL1 mRNA22634610
C492448ICG 001ICG 001 results in increased expression of ASXL1 mRNA26191083
D048628KetolidesKetolides analog results in increased expression of ASXL1 mRNA24967691
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ASXL1 gene20938992
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of ASXL1 mRNA23179753|2627250
C004925methylmercuric chloride"[NOG protein co-treated with methylmercuric chloride co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASXL1 mRNA"27188386
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of ASXL1 mRNA23649840
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of ASXL1 mRNA"25554681
C025589ochratoxin Aochratoxin A results in decreased acetylation of ASXL1 promoter29098329
C025589ochratoxin A[ochratoxin A results in decreased acetylation of ASXL1 promoter] which results in decreased expression of ASXL1 mRNA29098329|2909832
C025589ochratoxin Aochratoxin A results in decreased expression of ASXL1 mRNA29098329
C507134ON 01910ON 01910 results in increased expression of ASXL1 mRNA22351695
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of ASXL1 mRNA25729387
C045950propiconazolepropiconazole results in decreased expression of ASXL1 mRNA21278054
D012402RotenoneRotenone results in increased expression of ASXL1 mRNA19013527
D012643SeleniumSelenium results in decreased expression of ASXL1 mRNA19244175
C017947sodium arsenitesodium arsenite results in increased expression of ASXL1 mRNA28595984
D000952Antigens, Polyomavirus Transforming"Antigens, Polyomavirus Transforming results in increased expression of ASXL1 mRNA"26680231
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of ASXL1 mRNA25729387
D019772TopotecanTopotecan results in decreased expression of ASXL1 mRNA25729387
C012589trichostatin Atrichostatin A results in increased expression of ASXL1 mRNA24935251
C015559trimellitic anhydridetrimellitic anhydride results in increased expression of ASXL1 mRNA19042947
C057693troglitazonetroglitazone results in decreased expression of ASXL1 mRNA28973697
D014635Valproic AcidValproic Acid affects the expression of ASXL1 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of ASXL1 mRNA22083351|2800136
D014635Valproic AcidValproic Acid results in increased expression of ASXL1 mRNA23179753|2519280
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of ASXL1 gene25487561
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of ASXL1 gene25560391
D014750VincristineVincristine results in increased expression of ASXL1 mRNA23649840
D014810Vitamin EVitamin E results in decreased expression of ASXL1 mRNA19244175

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003677DNA binding-IEA-  
GO:0003682chromatin binding-IBA21873635  
GO:0003713transcription coactivator activity-ISS-  
GO:0005515protein binding-IPI16606617  18624398  19615732  20436459  22897849  27705803  
GO:0042974retinoic acid receptor binding-ISS-  
GO:0042975peroxisome proliferator activated receptor binding-IBA21873635  
GO:0042975peroxisome proliferator activated receptor binding-ISS-  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000902cell morphogenesis-IEA-  
GO:0003007heart morphogenesis-IEA-  
GO:0006351transcription, DNA-templated-IEA-  
GO:0009887animal organ morphogenesis-IBA21873635  
GO:0016579protein deubiquitination-TAS-  
GO:0030097hemopoiesis-IEA-  
GO:0032526response to retinoic acid-ISS-  
GO:0035359negative regulation of peroxisome proliferator activated receptor signaling pathway-ISS-  
GO:0035522monoubiquitinated histone H2A deubiquitination-IDA20436459  
GO:0045599negative regulation of fat cell differentiation-ISS-  
GO:0045944positive regulation of transcription by RNA polymerase II-IBA21873635  
GO:0045944positive regulation of transcription by RNA polymerase II-ISS-  
GO:0048386positive regulation of retinoic acid receptor signaling pathway-ISS-  
GO:0048538thymus development-IEA-  
GO:0048539bone marrow development-IEA-  
GO:0048872homeostasis of number of cells-IEA-  
GO:0060430lung saccule development-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000790nuclear chromatinCOLOCALIZES_WITHIBA21873635  
GO:0005634nucleusCOLOCALIZES_WITHIBA21873635  
GO:0005654nucleoplasm-TAS-  
GO:0035517PR-DUB complex-IBA21873635  
GO:0035517PR-DUB complex-IDA20436459  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-392499Metabolism of proteinsTAS
R-HSA-5688426DeubiquitinationTAS
R-HSA-5689603UCH proteinasesTAS
R-HSA-597592Post-translational protein modificationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
28483762Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. (2017 Aug 10)Zink FBlood